Article
Biochemistry & Molecular Biology
Mostafa M. Ghorab, Aiten M. Soliman, Khaled El-Adl, Noura S. Hanafy
Summary: Here, we synthesized a series of new quinazoline sulfonamide conjugates 2-16 and evaluated their potential as anticancer agents by targeting EGFRT790M and VEGFR-2. The compounds were designed based on the structure requirements of the receptors and confirmed using spectral data. They were tested for cytotoxicity against four cancer cell lines and the most active compound (15) showed significant cytotoxic and inhibitory activity against EGFR and VEGFR.
BIOORGANIC CHEMISTRY
(2023)
Review
Biochemistry & Molecular Biology
Nichole E. M. Kaufman, Simran Dhingra, Seetharama D. Jois, Maria da Graca H. Vicente
Summary: EGFR and VEGFR are frequently overexpressed membrane-bound receptor tyrosine kinase proteins in cancers, making them attractive targets for imaging and therapy. Inhibition modalities commonly used to target these receptors include TKIs, antibodies, and nanobodies. Recent advances in molecular imaging techniques, particularly near-IR fluorescence imaging, show promise for cancer detection and treatment.
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Biochemistry & Molecular Biology
Yassine Riadi, Mubarak A. Alamri, Mohammed H. Geesi, El Hassane Anouar, Oussama Ouerghi, Alhumaidi B. Alabbas, Manal A. Alossaimi, Ali Altharawi, Oussama Dehbi, Safar M. Alqahtani
Summary: The study presents an efficient process for synthesizing a new ethyl 2-((3-(4-fluorophenyl)-6-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio) acetate and characterizes its cytotoxic and kinase inhibitory activities. The compound showed potent cytotoxicity against human cancer cell lines and inhibitory activity towards VEGFR-2 and EGFR tyrosine kinases, indicating its potential as an effective anti-cancer agent.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2022)
Article
Cell Biology
John Abousawan, Laura A. Orofiamma, Gregory D. Fairn, Costin N. Antonescu
Summary: The epidermal growth factor receptor (EGFR) controls many cellular functions by undergoing dimerization, phosphorylation, and activation of signals including the PI3K-Akt pathway upon ligand binding. The role of flotillin nanodomains in EGFR signaling remains unclear, as some studies suggest their involvement while others show limited effect. This study reveals that HER2 expression alters EGFR signaling duration and requires flotillin-1 and c-Src for Akt activation and cell proliferation.
JOURNAL OF CELL SCIENCE
(2023)
Article
Oncology
Monika Caban, Bettina Koblmueller, Diana Groza, Hemma H. Schueffl, Alessio Terenzi, Alexander Tolios, Thomas Mohr, Marlene Mathuber, Kushtrim Kryeziu, Carola Jaunecker, Christine Pirker, Bernhard K. Keppler, Walter Berger, Christian R. Kowol, Petra Heffeter
Summary: Through chemical modifications, KP2187 has similar activity and action as other clinically used EGFR inhibitors, without interfering with EGFR binding. In vitro and in vivo experiments have shown that KP2187 can significantly inhibit tumor cell proliferation and activate the EGFR signaling pathway. Moreover, KP2187 has a high synergistic effect with VEGFR inhibitors, indicating its potential as a hypoxia-activated prodrug.
Article
Chemistry, Multidisciplinary
Shi-Jie Hao, Ya-Xuan Zhu, Fu -Gen Wu
Summary: Researchers developed a membrane fusion liposome (MFL) loaded with a small-molecule tyrosine kinase inhibitor (TKI) and doxorubicin (Dox) to achieve tumor cell membrane fusion-mediated drug delivery and enhanced chemotherapy of drug-resistant tumor.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Biochemistry & Molecular Biology
Heba K. A. El-Mawgoud, Ahmed M. Fouda, Mohammed A. A. El-Nassag, Ahmed A. Elhenawy, Mohammed Y. Alshahrani, Ahmed M. El-Agrody
Summary: A series of novel oxygen-containing heterocyclic linked 1H-benzo[f]chromene moieties were designed and synthesized, showing anti-proliferative activity against cancer cell lines, particularly MCF-7, HCT-116, and HepG-2. The compounds exhibited potential mechanisms involving cell cycle arrest and inhibition of topoisomerase enzymes.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Article
Medicine, General & Internal
Jana K. Striefler, Jens M. Stieler, Christopher C. M. Neumann, Dominik Geisel, Pirus Ghadjar, Marianne Sinn, Thomas Malinka, Johann Pratschke, Sebastian Stintzing, Helmut Oettle, Hanno Riess, Uwe Pelzer
Summary: This study aimed to determine the maximum tolerable dose of lapatinib in combination with platinum-containing chemotherapy in refractory pancreatic cancer, and to evaluate its safety and efficacy. The maximum tolerable dose was found to be 1250 mg/day, and the combination of lapatinib with platinum-containing chemotherapy was deemed safe in patients with refractory pancreatic cancer.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Xiaoqing Yu, Jiamin Sheng, Guoqiang Pan, Yun Fan
Summary: The use of osimertinib can significantly improve the survival outcomes of patients with EGFR-mutated NSCLC with brain metastases, regardless of T790M status. Patients who undergo intracranial local radiotherapy can also achieve a survival benefit.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Cell Biology
Xue Bai, Pengyu Sun, Xinghao Wang, Changkun Long, Shuyun Liao, Song Dang, Shangshang Zhuang, Yongtao Du, Xinyi Zhang, Nan Li, Kangmin He, Zhe Zhang
Summary: HER2 belongs to the human epidermal growth factor receptor tyrosine kinase family and its overexpression or hyperactivation is a leading cause for multiple types of cancers. The molecular details for heterodimer assembly between HER2 and EGFR are not completely understood.
Review
Biochemistry & Molecular Biology
Xiu-Fang Li, Chen-Fu Liu, Guo-Wu Rao
Summary: The human epidermal growth factor receptor family, including HER1/EGFR/ErbB1, HER2/NEU/ErbB2, HER3/ErbB3 and HER4/ErbB4, belongs to transmembrane receptor tyrosine kinases (RTKs) and participates in signal transduction and oncogenesis. These receptors have similar structures, with extracellular and intracellular domains serving different functions.
CURRENT MEDICINAL CHEMISTRY
(2021)
Article
Multidisciplinary Sciences
Hyoung-oh Jeong, Hayoon Lee, Hyemin Kim, Jinho Jang, Seunghoon Kim, Taejoo Hwang, David Whee-Young Choi, Hong Sook Kim, Naeun Lee, Yoo Mi Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Semin Lee, Se-Hoon Lee
Summary: The study found that specific cell types such as lung epithelial precursor cells and transitional effector T cells, as well as an immunosuppressive microenvironment, were enriched in the MPE of EGFR TKI-resistant patients, potentially associated with their response to TKI therapy.
Article
Oncology
Luis D. Borrero-Garcia, Maria del Mar Maldonado, Julia Medina-Velazquez, Angel L. Troche-Torres, Luis Velazquez, Nilmary Grafals-Ruiz, Suranganie Dharmawardhane
Summary: Despite the availability of targeted therapies for cancers expressing oncogenic EGFR and HER2, resistance to therapy remains a challenge. In a study on breast cancer cells, gefitinib and lapatinib resistant variants exhibited enhanced mesenchymal and cancer stem cell-like characteristics, along with increased expression and activation of the small GTPase Rac, suggesting Rac inhibition as a potential strategy to overcome therapy resistance.
Article
Oncology
Katerina Kratochvilova, Peter Horak, Milan Esner, Karel Soucek, Dietmar Pils, Mariam Anees, Erwin Tomasich, Frantisek Drafi, Veronika Jurtikova, Ales Hampl, Michael Krainer, Petr Vanhara
INTERNATIONAL JOURNAL OF CANCER
(2015)
Article
Oncology
Fred Saad, Karim Fizazi, Viorel Jinga, Eleni Efstathiou, Peter C. Fong, Lowell L. Hart, Robert Jones, Raymond McDermott, Manfred Wirth, Kazuhiro Suzuki, David B. MacLean, Ling Wang, Hideyuki Akaza, Joel Nelson, Howard I. Scher, Robert Dreicer, Iain J. Webb, Ronald de Wit
Article
Oncology
Matthew Smith, Johann De Bono, Cora Sternberg, Sylvestre Le Moulec, Stephane Oudard, Ugo De Giorgi, Michael Krainer, Andries Bergman, Wolfgang Hoelzer, Ronald De Wit, Martin Boegemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houede, Syed Hussain, Elaine Lam, Jonathan Polikoff, Arnulf Stenzl, Paul Mainwaring, David Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi
JOURNAL OF CLINICAL ONCOLOGY
(2016)
Article
Urology & Nephrology
Stephane Oudard, Gero Kramer, Orazio Caffo, Lorraine Creppy, Yohan Lorio, Steinbjoern Hansen, Mats Holmberg, Frederic Rolland, Jean-Pascal Machiels, Michael Krainer
Article
Oncology
Wolfgang Lamm, Camilla Natter, Sophie Schur, Wolfgang J. Koestler, Alexander Reinthaller, Michael Krainer, Christoph Grimm, Reinhard Horvath, Gabriele Amann, Philipp Funovics, Thomas Brodowicz, Stephan Polterauer
Article
Oncology
Petr Vanhara, Peter Horak, Dietmar Pils, Mariam Anees, Michaela Petz, Wolfgang Gregor, Robert Zeillinger, Michael Krainer
INTERNATIONAL JOURNAL OF ONCOLOGY
(2013)
Article
Oncology
Eugene D. Kwon, Charles G. Drake, Howard I. Scher, Karim Fizazi, Alberto Bossi, Alfons J. M. van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fabio A. Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor E. Ciuleanu, Ernesto Korbenfeld, Lisa Sengelov, Steinbjorn Hansen, Christopher Logothetis, Tomasz M. Beer, M. Brent McHenry, Paul Gagnier, David Liu, Winald R. Gerritsen
Article
Oncology
Mariam Anees, Peter Horak, Ana-Iris Schiefer, Petr Vanhara, Ahmed El-Gazzar, Paul Perco, Barbara Kiesewetter, Leonhard Muellauer, Berthold Streubel, Markus Raderer, Michael Krainer
LEUKEMIA & LYMPHOMA
(2015)
Article
Oncology
Maximilian Marhold, Erwin Tomasich, Ahmed El-Gazzar, Gerwin Heller, Andreas Spittler, Reinhard Horvat, Michael Krainer, Peter Horak
MOLECULAR CANCER RESEARCH
(2015)
Article
Multidisciplinary Sciences
Thorsten Fuereder, Volker Wacheck, Sabine Strommer, Peter Horak, Marion Gerschpacher, Wolfgang Lamm, Danijel Kivaranovic, Michael Krainer
Article
Multidisciplinary Sciences
Richard Schwameis, Christoph Grimm, Edgar Petru, Camilla Natter, Christine Staudigl, Wolfgang Lamm, Heinz Koelbl, Michael Krainer, Thomas Brodowicz, Alexander Reinthaller, Stephan Polterauer
Article
Multidisciplinary Sciences
Peter Horak, Erwin Tomasich, Petr Vanhara, Katerina Kratochvilova, Mariam Anees, Maximilian Marhold, Christof E. Lemberger, Marion Gerschpacher, Reinhard Horvat, Maria Sibilia, Dietmar Pils, Michael Krainer
SCIENTIFIC REPORTS
(2014)
Review
Oncology
Christina Steinbach, Almas Merchant, Alexandru-Teodor Zaharie, Peter Horak, Maximilian Marhold, Michael Krainer
Summary: Prostate cancer is a leading cause of cancer-related deaths among men in the US and Europe. Conventional treatments have limitations, while immunotherapy, specifically cellular immunotherapy and chimeric antigen receptors (CAR) T-cell therapy, shows promise in targeting malignant cells. The complex microenvironment of the tumor greatly affects the success or failure of immunotherapies in prostate cancer.
Article
Oncology
Barbara Kiesewetter, Markus Raderer, Guenther G. Steger, Rupert Bartsch, Robert Pirker, Sabine Zoechbauer-Mueller, Gerald Prager, Michael Krainer, Matthias Preusser, Manuela Schmidinger, Christoph C. Zielinski
Article
Medicine, General & Internal
T. M. Beer, A. J. Armstrong, D. E. Rathkopf, Y. Loriot, C. N. Sternberg, C. S. Higano, P. Iversen, S. Bhattacharya, J. Carles, S. Chowdhury, I. D. Davis, J. S. de Bono, C. P. Evans, K. Fizazi, A. M. Joshua, C-S Kim, G. Kimura, P. Mainwaring, H. Mansbach, K. Miller, S. B. Noonberg, F. Perabo, D. Phung, F. Saad, H. I. Scher, M-E Taplin, P. M. Venner, B. Tombal
NEW ENGLAND JOURNAL OF MEDICINE
(2014)